# Study Evaluating CCI-779 in Relapsing Multiple Sclerosis

> **NCT00228397** · PHASE2 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 221 (actual)

## Conditions studied

- Multiple Sclerosis, Relapsing-Remitting

## Interventions

- **DRUG:** CCI-779

## Key facts

- **NCT ID:** NCT00228397
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-11
- **Primary completion:** 2005-11
- **Final completion:** 2005-11
- **Target enrollment:** 221 (ACTUAL)
- **Last updated:** 2013-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00228397

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00228397, "Study Evaluating CCI-779 in Relapsing Multiple Sclerosis". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00228397. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*